IMMUCELL Corp., a growing animal health company for the dairy and beef industries, announced July 9 that it has completed modifications to its manufacturing facility to produce pharmaceutical-grade nisin, the active ingredient in its Mast Out product, to address subclinical mastitis in lactating dairy cows.
ImmuCell said it will now start validation and testing of the new facility and processing equipment to complete the manufacturing requirements
All access premium subscription
This content requires a subscription to Feedstuffs in order to access. If you are a paid subscriber, use your email and password to Log In now.
Current Feedstuffs Subscribers: Online and mobile access are now included at no charge to you. To read this article, use your subscriber email and password to log-in to your account (or contact us for assistance in updating your account.)
Not Currently a Subscriber: Subscribe NOW to Feedstuffs and receive our print and/or digital publications, enewsletters and premium online content. Visit Feedstuffs.com and click on Subscribe at the top of the page for more information.
SUBSCRIBE NOW https://circulation.feedstuffs.com/Publications.aspx
TO RENEW YOUR SUBSCRIPTION https://circulation.feedstuffs.com/SubscriptionOffers.aspx